Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ozempic® (semaglutide) approved in the US

Novo Nordisk A/S
Posted on: 05 Dec 17

Bagsværd, Denmark, 5 December 2017 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Ozempic ® (semaglutide injection). Ozempic ® is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus. 

Ozempic ® , the approved brand name for once-weekly semaglutide in the US, is a glucagon-like peptide 1 (GLP-1) receptor agonist. The approval of Ozempic ® is based on the results from the SUSTAIN clinical trial programme and follows a positive recommendation from an FDA Advisory Committee meeting on 18 October 2017. In people with type 2 diabetes, Ozempic ® produced clinically meaningful and statistically significant reductions in HbA 1c compared with placebo, sitagliptin, exenatide extended-release and insulin glargine U100. Furthermore, in the trials, treatment with Ozempic ® resulted in statistically significant reductions in body weight. Ozempic ® demonstrated a safe and well-tolerated profile across the SUSTAIN programme with the most common adverse event being mild to moderate nausea, which diminished over time.

Ozempic ® is approved for use in two therapeutic dosages, 0.5 mg and 1 mg, and will be launched in the Ozempic ® Pen, the latest generation of Novo Nordisk prefilled devices.

Novo Nordisk will, as part of the post-approval requirements, conduct a paediatric trial in adolescents under 18 years of age and will add Ozempic ® to the 15-year MTC (medullary thyroid carcinoma) registry that is being conducted for all other long-acting GLP-1 products.    

"We are very excited about the first approval of Ozempic ® and look forward to making this important innovation available to people in the US with type 2 diabetes in the beginning of 2018," said Mads Krogsgaard Thomsen, executive vice president and chief science officer. "Type 2 diabetes is a complex disease, but with the unique clinical profile of Ozempic ® , we believe it has the potential to set a new standard for the treatment of the disease."

Conference call

On 6 December 2017 at 12.00 pm CET, corresponding to 6.00 am EST, a conference call for investors will be held. Investors will be able to listen in via a link on the investor section of

About Ozempic ®              

Ozempic ® (semaglutide) is a once-weekly analogue of human glucagon-like peptide-1 (GLP-1) that has been developed for the treatment of type 2 diabetes. The review of Ozempic ® is based on the SUSTAIN programme, a global clinical development programme that comprises eight phase 3a trials, encompassing more than 8,000 adults with type 2 diabetes. The phase 3a programme involves a broad range of people with type 2 diabetes, including some with high cardiovascular risk profiles and people with and without renal disease.

Ozempic ® is currently under review by several regulatory agencies, including the European Medicines Agency and the Japanese Pharmaceuticals and Medical Devices Agency.

Further information

Katrine Sperling+45 4442 6718
Ken Inchausti (US)+1 609 786 8316
Investors :    
Peter Hugreffe Ankersen+45 3075 9085
Hanna Ögren+45 3079 8519
Anders Mikkelsen+45 3079 4461
Christina Kjær+45 3079 3009
Kasper Veje (US)+1 609 235 8567

Company announcement No 90 / 2017 


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via GlobeNewswire

Last updated on: 06/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.